About Hemab Therapeutics Holdings Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://ir.hemab.com
Frequently Asked Questions
What is the 52-week range for COAG?
The 52-week high is $55.42 and the 52-week low is $23.0001.
What is the P/E ratio for COAG?
The P/E ratio data is currently unavailable.
What is the dividend yield for COAG?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
ROE data is currently unavailable.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
P/B ratio data is currently unavailable.
Analyst Recommendation Trends
Wall Street analyst consensus for COAG over the last few months:
Latest COAG News
Hemab Therapeutics Holdings (COAG) Joins Russell Indices, Is The Stock Still Trading At A Discount?
Board appointment and index inclusion frame Hemab Therapeutics Holdings Hemab Therapeutics Holdings (COAG) has appointed Keli Walbert to its Board and Audit Committee, and the stock has also been added to multiple Russell indices, drawing fresh attention from institutional screens. For Hemab Therapeutics Holdings, the recent HMB-003 trial initiation and a wave of Russell index inclusions have arrived during a choppy period, with the 30-day share price return down 26.14% and the year-to-date...
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the BoardCAMBRIDGE, Mass. and COPENHAGEN, Denmark, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the appointment of Keli Walbert to its Board of Directors, effective September 24, 2026. Ms. Walbe
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecologists, with approximately 23 million seeking care from a healthcare professional in the U.S. last year. It is the leading cause of iron deficiency and anemia among premenopausal women, and the primary symptom driving hysterectomies in the U.S. CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: CO
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-24 | Walbert Keli | +36,000 | - | - |
| 2026-06-16 | RA Capital Healthcare Fund LP | +61,523 | $24.98 | $1,536,845 |
| 2026-06-15 | RA Capital Healthcare Fund LP | +6,146 | $24.89 | $152,974 |
| 2026-05-20 | RA Capital Healthcare Fund LP | +996 | $24.94 | $24,840 |
| 2026-05-19 | RA Capital Healthcare Fund LP | +3,802 | $24.97 | $94,936 |
| 2026-05-12 | RA Capital Healthcare Fund LP | +6,387 | $24.9 | $159,036 |
| 2026-05-11 | RA Capital Healthcare Fund LP | +25,720 | $25 | $643,000 |
| 2026-05-11 | RA Capital Healthcare Fund LP | +14,149 | $24.47 | $346,226 |
| 2026-05-08 | RA Capital Healthcare Fund LP | +1,483 | $24.98 | $37,045 |
| 2026-05-07 | RA Capital Healthcare Fund LP | +1,985 | $24.95 | $49,526 |
| 2026-05-07 | RA Capital Healthcare Fund LP | +7,921 | $24.34 | $192,797 |
| 2026-05-06 | RA Capital Healthcare Fund LP | +53,407 | $24.83 | $1,326,096 |
| 2026-05-06 | RA Capital Healthcare Fund LP | +14,611 | $23.77 | $347,303 |
| 2026-05-05 | RA Capital Healthcare Fund LP | +10,268 | $25 | $256,700 |
| 2026-05-05 | RA Capital Healthcare Fund LP | +87,143 | $24.59 | $2,142,846 |
| 2026-05-04 | Novo Holdings A/S | -32,695 | - | - |
| 2026-05-04 | Novo Holdings A/S | -62,121 | - | - |
| 2026-05-04 | Novo Holdings A/S | -71,866 | - | - |
| 2026-05-04 | Novo Holdings A/S | -23,343 | - | - |
| 2026-05-04 | Novo Holdings A/S | +4,180,550 | - | - |
| 2026-05-04 | RA Capital Healthcare Fund LP | -10,054 | - | - |
| 2026-05-04 | RA Capital Healthcare Fund LP | -56,972 | - | - |
| 2026-05-04 | RA Capital Healthcare Fund LP | -18,146 | - | - |
| 2026-05-04 | RA Capital Healthcare Fund LP | -42,341 | - | - |
| 2026-05-04 | RA Capital Healthcare Fund LP | -27,720 | - | - |
| 2026-05-04 | RA Capital Healthcare Fund LP | -64,680 | - | - |
| 2026-05-04 | RA Capital Healthcare Fund LP | +133,750 | $18 | $2,407,500 |
| 2026-05-04 | RA Capital Healthcare Fund LP | +2,541,250 | $18 | $45,742,500 |
| 2026-05-04 | RA Capital Healthcare Fund LP | +221,188 | - | - |
| 2026-05-04 | RA Capital Healthcare Fund LP | +1,009,052 | - | - |
| 2026-05-04 | RA Capital Healthcare Fund LP | +3,607,846 | - | - |
| 2026-05-04 | MARAGANORE JOHN | -817 | - | - |
| 2026-05-04 | MARAGANORE JOHN | -817 | - | - |
| 2026-05-04 | MARAGANORE JOHN | +17,974 | - | - |
| 2026-05-04 | MARAGANORE JOHN | +17,974 | - | - |
| 2026-04-30 | Behrndt-Eriksen Mads Nikolaj | +49,016 | - | - |
| 2026-04-30 | Madigan Catherine | +49,016 | - | - |
| 2026-01-29 | Behrndt-Eriksen Mads Nikolaj | +195,206 | - | - |
| 2026-01-29 | Madigan Catherine | +145,134 | - | - |
| 2026-01-29 | MARAGANORE JOHN | +107,338 | - | - |